Fate’s off-the-shelf CAR-T therapy shows early promise in treatment-resistant autoimmune disease

“We were not expecting to see clinical responses so early,” Vaneet Sandhu, M.D., rheumatologist and vice president of clinical development at Fate Therapeutics, told Fierce.